Oncotarget

Research Perspectives:

Novel Therapeutic Targets in the Brain Tumor Microenvironment

Joanna J. Phillips _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:568-575. https://doi.org/10.18632/oncotarget.526

Metrics: PDF 1240 views  |   HTML 1861 views  |   ?  


Abstract

Joanna J. Phillips1,2

1 Department of Neurological Surgery, University of California San Francisco

2 Department of Pathology, Division of Neuropathology, University of California San Francisco

Correspondence:

Joanna J. Phillips, email:

Keywords: Glioblastoma, proteoglycans, HSPG, sulfs, sulf2, tumor microenvironment

Received: May 06, 2012, Accepted: May 23, 2012, Published: May 25, 2012

Abstract

Glioblastoma (GBM), a highly malignant brain tumor of adults and children, diffusely invades within the non-neoplastic brain. Despite aggressive current therapeutic interventions, improved therapeutic strategies are greatly needed. Interactions between the tumor and constituents of its microenvironment are known to regulate malignancy, and heparan sulfate proteoglycans (HSPGs) are important as they bind diverse extracellular proteins, including growth factors and cell adhesion molecules, regulating the activity of several ligand-mediated signaling pathways. Recent work from our group described a mechanism by which GBM regulates PDGFR-alpha signaling via enzymatic alteration of heparan sulfate proteoglycans (HSPGs) in the extracellular microenvironment. Blocking tumor-induced alterations of HSPGs, which can be achieved by pharmacological strategies, would potentially inhibit multiple oncogenic signaling pathways in tumor cells and disrupt critical tumor-microenvironment interactions. Here we examine HSPGs and the enzymes that modify them in GBM. We compare their expression across tumor subtypes, their potential roles in oncogenesis, and their potential as novel therapeutic targets in GBM.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 526